Welcome to our dedicated page for Orasure Tech news (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on Orasure Tech stock.
OraSure Technologies Inc (OSUR) is a leader in non-invasive diagnostic solutions and molecular testing systems for global healthcare markets. This comprehensive news hub provides investors and healthcare professionals with essential updates on corporate developments, regulatory milestones, and product innovations.
Access timely updates including earnings reports, FDA clearances, clinical trial results, and strategic partnerships. Our curated collection features press releases covering oral fluid diagnostics advancements, molecular testing solutions, and cryosurgical product developments – all critical for assessing the company's market position.
Key content categories include financial performance disclosures, manufacturing expansion announcements, research collaborations, and public health initiatives. The archive serves as a vital resource for tracking OSUR's contributions to HIV testing, substance abuse screening, and genetic material stabilization technologies.
Bookmark this page for streamlined monitoring of OraSure's operational updates and industry leadership in medical device innovation. Check regularly for authoritative information supporting informed analysis of this diagnostic technology pioneer.
OraSure Technologies (NASDAQ: OSUR) reported a total revenue of $233.7 million for 2021, representing a 36% increase year-over-year. In Q4 alone, revenue reached $63.6 million, a 1% rise from Q4 2020. The InteliSwab® product saw significant growth, with Q4 revenues of $14.7 million, up 92% sequentially. However, the company faced challenges, including a net loss of ($10.4) million for Q4 and a 27% decline in Molecular Solutions revenues. Management is optimistic about InteliSwab®'s growth potential and plans for further scaling production.
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced its earnings conference call for the fourth quarter of 2021, scheduled for February 23, 2022, at 5:00 PM ET. A press release detailing the financial results will be distributed at 4:01 PM ET on the same day. Investors can participate by calling (888) 771-4371 domestically or (847) 585-4405 internationally, using Conference ID #50277718. The call will also be available via webcast on OraSure’s Investor Relations page, with a replay accessible for 14 days post-call.
OraSure Technologies (NASDAQ: OSUR) announced FDA authorization for its InteliSwab® COVID-19 rapid tests for children aged 2 to 14. The tests demonstrated an 85% positive percent agreement and 93% overall accuracy, highlighting their usability with a 96% success rate in administration by parents. The launch of InteliSwab® Connect reporting app was also announced to aid in COVID-19 prevalence tracking. These developments are significant for increasing testing access among children and supporting public health efforts.
OraSure Technologies (NASDAQ: OSUR) has launched its OraQuick® HIV Self-Test in Europe, expanding access to its in-home oral swab test for HIV-1 and HIV-2. Available in the UK, Germany, France, Italy, Spain, and Portugal, this CE-marked test requires no blood sample and offers results in just 20 minutes with over 99% accuracy. Since its U.S. debut in 2012, OraSure has distributed 76 million tests globally, focusing on areas with high HIV prevalence. The initiative aligns with increasing global testing policies and aims to enhance healthcare accessibility across Europe.
OraSure Technologies (NASDAQ: OSUR) announced that its InteliSwab® COVID-19 rapid tests effectively detect the Omicron variant as well as previous strains, including Delta and Alpha. Independent lab studies confirmed that the tests identified the Omicron variant at the same viral load as earlier variants. The tests are user-friendly, providing results in 30 minutes without the need for additional instruments. The InteliSwab® has received Emergency Use Authorization (EUA) from the FDA for over-the-counter and professional use. OraSure continues to adapt to evolving COVID-19 challenges.
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced its preliminary Q4 2021 financial outlook, expecting total revenue of approximately $60 million, with InteliSwab™ sales around $12 million. The Company is addressing technology transfer challenges to scale up production and capitalize on demand. A strategic review is underway to enhance shareholder value, coupled with leadership changes including CEO Stephen Tang's departure on March 31, 2022. The Board aims for improved operational performance and has appointed new presidents for Diagnostics and Molecular Solutions.
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced that its 2022 Annual Meeting of Stockholders will take place on May 17, 2022, at 10:00 a.m. EDT, with a record date of March 27, 2022. The meeting will be conducted virtually via a live webcast, allowing only stockholders of record to vote. Additional details will be provided later. OraSure Technologies specializes in rapid diagnostic tests, sample collection, and molecular services, serving various sectors globally, including clinical laboratories and public health organizations.
OraSure Technologies (NASDAQ: OSUR) will ring the Nasdaq closing bell on November 30, 2021, to honor World AIDS Day.
The company has made significant advancements in HIV testing since the FDA approved its first rapid test in 2002, with over 70 million tests used worldwide.
The event will feature a panel discussing the history of the HIV epidemic. OraSure continues its commitment by supporting global HIV testing efforts.
CEO Stephen S. Tang emphasizes the need for continued action against the HIV epidemic, marking 40 years of progress.
OraSure Technologies announces participation in two upcoming conferences, with Dr. Stephen S. Tang, President and CEO, speaking at both. The first is the Stephens Annual Investment Conference on November 29, 2021, at 12:00 pm ET, followed by the Evercore 4th Annual HealthConx Virtual Conference on December 1, 2021, at 1:50 pm ET. Both events will be webcasted live. Interested parties can access the presentations and replays on the OraSure Technologies website for 14 days.
OraSure Technologies (NASDAQ: OSUR) announced the retirement of Jack E. Jerrett, Senior VP and General Counsel, after nearly 21 years. Effective December 31, 2021, he will be succeeded by Agnieszka M. Gallagher, previously Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals. Gallagher brings over 20 years of legal and compliance experience, including roles at major companies like ViiV Healthcare and GSK Vaccines. OraSure aims to maintain its leadership in diagnostic testing and sample collection technologies with this transition.
FAQ
What is the current stock price of Orasure Tech (OSUR)?
What is the market cap of Orasure Tech (OSUR)?
